Activated protein C: Cost-effective or costly?

Critical Care

Volumn 11, Issue 5, 2007, Pages

  Brar, Savtaj Singh ^a   Manns, Braden J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ANTICOAGULANT AGENT; PROTEIN C;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MEDICAL TECHNOLOGY; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEPSIS; SURVIVAL RATE; COST BENEFIT ANALYSIS; ECONOMICS;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; HUMANS; PROTEIN C; SEPSIS;

EID: 44449133858     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6090     Document Type: Note

References (13)

1. Dhainaut J-F Payet S Vallet B Riou-França L Annane D Bollaert P-E Le Tulzo Y Runge I Malledant Y Guidet B et al. Cost-effectiveness of activated protein C in real-life clinical practice Crit Care 2007, 11:R99. 10.1186/cc6116 17822547
2. Cox HL Laupland KB Manns BJ Economic evaluation in critical care medicine J Crit Care 2006, 21:117-124. 10.1016/j.jcrc.2006.02.003 16769454
3. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW et al. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001 11236773
4. Angus DC Linde-Zwirble WT Clermont G Ball DE Basson BR Ely EW Laterre PF Vincent JL Bernard G van Hout B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Crit Care Med 2003, 31:1-11. 10.1097/00003246-200301000-00001 12544986
5. Betancourt M McKinnon PS Massanari RM Kanji S Bach D Devlin JW An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures Pharmacoeconomics 2003, 21:1331-1340. 10.2165/00019053-200321180-00004 14750900
6. Green C Dinnes J Takeda AL Cuthbertson BH Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Int J Technol Assess Health Care 2006, 22:90-100. 16673685
7. Manns BJ Lee H Doig CJ Johnson D Donaldson C An economic evaluation of activated protein C treatment for severe sepsis N Engl J Med 2002, 347:993-1000. 10.1056/NEJMsa020969 12324556
8. Riou Franca L Launois R Le Lay K Aegerter P Bouhassira M Meshaka P Guidet B Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Int J Technol Assess Health Care 2006, 22:101-108. 16673686
9. Revicki DA Frank L Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies Pharmacoeconomics 1999, 15:423-434. 10.2165/00019053-199915050-00001 10537960
10. Sculpher MJ Claxton K Drummond M McCabe C Whither trial-based economic evaluation for health care decision making? Health Econ 2006, 15:677-687. 10.1002/hec.1093 16491461
11. Drummond M Mason A Towse A The desirability and feasibility of economic studies of drugs post-launch Eur J Health Econ 2006, 7:5-6. 10.1007/ s10198-006-0337-2 16470374
12. Mackenzie AF Activated protein C: Do more survive? Intensive Care Med 2005, 31:1624-1626. 10.1007/s00134-005-2829-4 16228174
13. Wiedermann CJ When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated) Intensive Care Med 2006, 32:604. 10.1007/ s00134-006-0086-9 16508757